Literature DB >> 21309124

Pharmacotherapy of post-traumatic stress disorder.

Lakshmi N Ravindran1, Murray B Stein.   

Abstract

Post-traumatic stress disorder (PTSD) is a prevalent psychiatric disorder that may result in significant social and occupational debilitation unless symptoms are recognized and treated appropriately. Considerable research effort has been devoted over the last 20 years to developing effective pharmacological treatments for this illness. At this time, the bulk of the agents investigated include antidepressants, anticonvulsants, atypical antipsychotics, benzodiazepines, and antiadrenergic agents. Herein, we review the existing evidence base for these different classes of psychotropics in PTSD. Emphasis is placed on discussion of evidence stemming from randomized placebo-controlled clinical trials wherever possible. A brief description of novel agents that have shown initial promise for PTSD treatment is also provided.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21309124     DOI: 10.1007/7854_2009_15

Source DB:  PubMed          Journal:  Curr Top Behav Neurosci        ISSN: 1866-3370


  15 in total

Review 1.  Pharmacological treatment of PTSD - established and new approaches.

Authors:  Thomas Steckler; Victoria Risbrough
Journal:  Neuropharmacology       Date:  2011-06-29       Impact factor: 5.250

2.  Serotonin transporter-linked polymorphic region genotypes in relation to stress conditions among patients with papillary thyroid carcinoma.

Authors:  Feng-Xia Chen; Xian-Shan Chen; Jun-Cheng Guo; Bao-Ai Zheng; Min Guo
Journal:  Int J Clin Exp Pathol       Date:  2019-03-01

3.  Pilot study of the effect of lipophilic vs. hydrophilic beta-adrenergic blockers being taken at time of intracardiac defibrillator discharge on subsequent PTSD symptoms.

Authors:  Chaya G Bhuvaneswar; Jeremy N Ruskin; Anna Roglieri Katzman; Nellie Wood; Roger K Pitman
Journal:  Neurobiol Learn Mem       Date:  2014-01-03       Impact factor: 2.877

Review 4.  Treating nightmares and insomnia in posttraumatic stress disorder: a review of current evidence.

Authors:  Carla M Nappi; Sean P A Drummond; Joshua M H Hall
Journal:  Neuropharmacology       Date:  2011-03-17       Impact factor: 5.250

5.  Escitalopram reversed the traumatic stress-induced depressed and anxiety-like symptoms but not the deficits of fear memory.

Authors:  Chen-Cheng Lin; Che-Se Tung; Yia-Ping Liu
Journal:  Psychopharmacology (Berl)       Date:  2016-01-07       Impact factor: 4.530

Review 6.  Targeting memory processes with drugs to prevent or cure PTSD.

Authors:  Christopher K Cain; George D Maynard; John H Kehne
Journal:  Expert Opin Investig Drugs       Date:  2012-07-27       Impact factor: 6.206

Review 7.  Inflammation-driven brain and gut barrier dysfunction in stress and mood disorders.

Authors:  Ellen Doney; Alice Cadoret; Laurence Dion-Albert; Manon Lebel; Caroline Menard
Journal:  Eur J Neurosci       Date:  2021-05-17       Impact factor: 3.698

8.  The effectiveness of cognitive behavioral therapy with respect to psychological symptoms and recovering autobiographical memory in patients suffering from post-traumatic stress disorder.

Authors:  Fatemehsadat Akbarian; Hafez Bajoghli; Mohammad Haghighi; Nadeem Kalak; Edith Holsboer-Trachsler; Serge Brand
Journal:  Neuropsychiatr Dis Treat       Date:  2015-02-19       Impact factor: 2.570

9.  An examination of the association between 5-HTTLPR, combat exposure, and PTSD diagnosis among U.S. veterans.

Authors:  Yutao Liu; Melanie E Garrett; Michelle F Dennis; Kimberly T Green; Allison E Ashley-Koch; Michael A Hauser; Jean C Beckham; Nathan A Kimbrel
Journal:  PLoS One       Date:  2015-03-20       Impact factor: 3.240

10.  Anxiolytic effects of flavonoids in animal models of posttraumatic stress disorder.

Authors:  Li-Ming Zhang; Jia-Zhi Yao; Yang Li; Kai Li; Hong-Xia Chen; You-Zhi Zhang; Yun-Feng Li
Journal:  Evid Based Complement Alternat Med       Date:  2012-12-13       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.